An update on the pathology and clinical management of gouty arthritis
Open Access
- 9 November 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 31 (1), 13-21
- https://doi.org/10.1007/s10067-011-1877-0
Abstract
Gouty arthritis is an inflammatory condition associated with debilitating clinical symptoms, functional impairments, and a substantial impact on quality of life. This condition is initially triggered by the deposition of monosodium urate crystals into the joint space. This causes an inflammatory cascade resulting in the secretion of several proinflammatory cytokines and neutrophil recruitment into the joint. While generally effective, currently available agents are associated with a number of adverse events and contraindications that complicate their use. Based on our increased understanding of the inflammatory pathogenesis of gouty arthritis, several new agents are under development that may provide increased efficacy and reduced toxicity.This publication has 36 references indexed in Scilit:
- Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional TreatmentJama-Journal Of The American Medical Association, 2011
- Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: Results of a multicenter, phase II, dose‐ranging studyArthritis & Rheumatism, 2010
- The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot studyAnnals Of The Rheumatic Diseases, 2009
- Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol–conjugated uricase) in patients with treatment‐failure gout: Results of a phase II randomized studyArthritis & Rheumatism, 2008
- Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering TherapyNucleosides, Nucleotides and Nucleic Acids, 2008
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IIArthritis & Rheumatism, 2007
- British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of GoutRheumatology, 2007
- Prevalence of Comorbid Conditions and Prescription Medication Use Among Patients With Gout and Hyperuricemia in a Managed Care SettingJCR: Journal of Clinical Rheumatology, 2004
- Purine-Rich Foods, Dairy and Protein Intake, and the Risk of Gout in MenThe New England Journal of Medicine, 2004
- The association between gout and nephrolithiasis: The National Health and Nutrition Examination Survey III, 1988-1994American Journal of Kidney Diseases, 2002